Human pain models have been established as effective, cost-efficient tools for evaluating the efficacy of analgesic drugs. Three acute pain models have been most commonly used in recent years: bunionectomy, third molar extraction and abdominoplasty. Each of these...
As most medications are primarily excreted through the kidneys or liver, most drugs in development will require a renal and/or hepatic insufficiency trial to assess the impact of organ impairment on the pharmacokinetic (PK) parameters of the investigational product....
In today’s rapidly evolving pharmaceutical landscape, cognitive safety is emerging as a critical factor that can set products apart in the marketplace. This session will explore the strategic importance of incorporating cognitive assessments as a safety endpoint in...
Dr. Sheldon H. Preskorn’s presentation, “From Chance Discovery to Molecular Biology,” highlights the evolution of psychiatric drug development, from early chance observations to sophisticated molecular biology approaches. The talk explores key...
As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. This webinar delves into AI’s significant impact on streamlining clinical project...
Discover this groundbreaking webinar delving into the latest insights from the Cross-Company Abuse Liability Council (CCALC) and The Food and Drug Administration (FDA) in drug development and clinical evaluation of human drug abuse and dependence potential. This...
Recent Comments